

1 **Ancient *Mycobacterium leprae* genomes from the mediaeval sites of**
2 **Chichester and Raunds in England**

3

4 Ammielle Kerudin^a, Romy Müller^a, Jo Buckberry^b, Christopher J. Knüsel^c, Terence A. Brown^{a,*}

5

6 ^a *Department of Earth and Environmental Sciences, Manchester Institute of Biotechnology, University*
7 *of Manchester, Manchester M1 7DN, UK*

8 ^b *Biological Anthropology Research Centre, School of Archaeological and Forensic Sciences,*
9 *University of Bradford, Bradford BD7 1DP, UK*

10 ^c *UMR5199 PACEA, Bâtiment B8, Allée Geoffroy Saint Hilaire, CS 50023, Pessac Cedex, France*
11 *33615*

12

13 Corresponding author

14 *Email address:* terry.brown@manchester.ac.uk

15 **Abstract**

16 We examined six skeletons from mediaeval contexts from two sites in England for the presence of
17 *Mycobacterium leprae* DNA, each of the skeletons displaying osteological indicators of leprosy.
18 Polymerase chain reactions directed at the species-specific RLEP multicopy sequence produced
19 positive results with three skeletons, these being among those with the clearest osteological signs of
20 leprosy. Following in-solution hybridization capture, sufficient sequence reads were obtained to cover
21 >70% of the *M. leprae* genomes from these three skeletons, with a mean read depth of 4–10×. Two
22 skeletons from a mediaeval hospital in Chichester, UK, dating to the 14th–17th centuries AD, contained
23 *M. leprae* strains of subtype 3I, which has previously been reported in mediaeval England. The third
24 skeleton, from a churchyard cemetery at Raunds Furnells, UK, dating to the 10th to mid-12th centuries
25 AD, carried subtype 3K, which has been recorded at 7th–13th century AD sites in Turkey, Hungary and
26 Denmark, but not previously in Britain. We suggest that travellers to the Holy Land might have been
27 responsible for the transmission of subtype 3K from southeast Europe to Britain.

28

29 *Keywords:* Ancient DNA, Leprosy, Mediaeval England, *Mycobacterium leprae*, Palaeopathology

30

31 **1. Introduction**

32 Leprosy is a slowly progressive, chronic granulomatous disease caused by *Mycobacterium leprae*
33 (Hansen, 1874) and potentially, in a minority of cases, by the more recently characterised agent
34 described as *Mycobacterium lepromatosis* (Han et al., 2008). The primary symptoms are granulomas
35 of the skin, peripheral nerves and respiratory tract, but sometimes the eyes, skeleton and nasal
36 cartilage are also affected (Britton and Lockwood, 2004). The bacilli accumulate in the extremities of
37 the body, invading the Schwann cells causing nerve damage followed by a gradual sensory loss and
38 eventually leading to deformities and disabilities (Masaki et al., 2013). A multi-drug regime comprising
39 dapsone, rifampicin and clofazimine has been used successfully to treat 16 million leprosy patients
40 over the last twenty years, but new infections are frequent with 210,671 leprosy cases reported in
41 2017 (World Health Organisation, 2018). With the highest incidence of new cases occurring in
42 northeast South America, central Africa and the Indian subcontinent, leprosy is classified as a
43 ‘neglected tropical disease’ (Lenk et al., 2018). Although the disease itself is curable, leprosy-related
44 deformities and disabilities are irreversible, especially when treatment has been delayed (Britton and
45 Lockwood, 2004). Some 2–3 million people worldwide display post-leprosy disfigurements, and many
46 are subject to the social discrimination referred to as leprosy stigma, which in the past was driven by
47 misunderstandings regarding transmission of the disease, and which still persists today in some parts
48 of the world (Grzybowski et al., 2016).

49 Leprosy is one of the oldest diseases known to humankind. Although ambiguous, textual
50 references to skin diseases in the Indian *Atharva Veda* and *Laws of Manu* (2000–1500 BC)
51 (Bloomfield, 2004) and the Egyptian Ebers papyrus (1550 BC) (Hulse, 1972) have been identified as
52 leprosy, and there are more recent accounts of the disease dating from the 6th century BC to 1st
53 century AD from India (Bhishagratna, 1996), China (McLeod and Yates, 1981; Leung, 2008), Greece
54 (Pinhasi et al., 2005) and Rome (Roberts and Manchester, 2010). Additional evidence is provided by

55 palaeopathological examination of archaeological skeletons for the osteological manifestations of the
56 disease that can be observed in the hands, feet, facial bones, tibiae and fibulae of affected skeletons
57 (Ortner, 2003). The oldest skeleton displaying such lesions dates to 2000 BC, from Rajasthan in
58 northwest India (Robbins et al., 2009), in accordance with the Indian textual references from the same
59 period. It has been suggested that the disease was brought to Europe and Northern Africa by the
60 armies of Alexander the Great, with their return from the Indian campaign in 327–326 C (Roberts and
61 Manchester, 2010). There is skeletal evidence of leprosy in Egypt at 200 BC (Dzierzykay-Rogalski,
62 1980) and in Western Europe from the 4th century AD (Reader, 1974). However, the disease appears
63 to have been uncommon in Europe until the Mediaeval period, when skeletons displaying lesions
64 become more abundant (Roberts and Manchester, 2010). In Britain, the prevalence of leprosy peaks
65 in the 13th century AD and then declines during the 15th century AD before becoming uncommon
66 again from the 16th century AD onwards (for a review of the osteological evidence for Britain, see
67 Roberts, 2002), possibly because of improved social conditions combined with the development of
68 enhanced resistance to the disease among the human population (Schuenemann et al., 2013). The
69 decline is mirrored in continental Europe (Bennike, 2002), although the disease persisted in some
70 parts of Norway and elsewhere until the 19th century AD (Baldsen, 2001).

71 About 5% of leprosy cases develop skeletal changes, and the lesions used in osteological
72 assessment of the disease can be ambiguous. An important adjunct to palaeopathological analysis
73 has therefore been provided by the detection and sequencing of *M. leprae* DNA, which is sometimes
74 preserved in archaeological skeletons displaying osteological lesions and has also occasionally been
75 detected in skeletons free from such lesions (Donoghue et al., 2017). Initially, ancient DNA typing was
76 used mainly to support osteological identifications of leprosy (Rafi et al., 1994; Taylor et al., 2000,
77 2006; Donoghue et al., 2001, 2005, 2015; Inskip et al., 2015), but with increasing knowledge of
78 genomic diversity among extant *M. leprae* strains it has become possible to contextualise ancient
79 DNA data within an evolutionary scheme for the bacterium (Schuenemann et al., 2018). The *M.*
80 *leprae* genome is 3.27 Mb, substantially smaller than the 4.42 Mb genome of *Mycobacterium*
81 *tuberculosis*, and contains relatively high number of pseudogenes, indicative of reductive evolution
82 (Singh and Cole, 2011). Different strains show high sequence similarity, with only a small number of
83 variations in the form of indels (short insertions or deletions) and single nucleotide polymorphisms
84 (SNPs) (Monot et al., 2009). The SNP variations were initially used to divide modern isolates into four
85 main types and 16 subtypes called 1A–1D, 2E–2H, 3I–3M and 4N–4P. With the addition of more
86 sequences, this classification has become elaborated into a phylogenetic scheme comprising six main
87 branches, with branches 1 and 2 corresponding to types 1 and 2, respectively, branch 3 to subtype 3I,
88 branch 4 to the type 4 strains and also subtypes 3L and 3M, and branches 5 and 0 to different
89 variants of subtype 3K (Schuenemann et al., 2013, 2018). Among modern isolates, variants display
90 geographical partitioning with branch 1 associated with South and East Asia, branch 2 with south and
91 Southwest Asia, branch 3 with Central and North America, branch 4 with West Africa and South
92 America, and branches 5 and 0 with East Asia (Monot et al., 2009; Schuenemann et al., 2013).
93 However, these present-day distributions do not reflect the full complexity of *M. leprae* distribution in

94 the past, especially in mediaeval Europe where subtypes within branches 2, 3, 4 and 0 have been
95 identified in skeletons dating from the 5th–14th centuries AD (Singh and Cole, 2011).

96 Although *M. leprae* aDNA has been reported from a number of British sites (reviewed by
97 Donoghue et al., 2017), sufficient data for subtype identification has only been obtained from six
98 skeletons from the St Mary Magdalen *leprosarium* in Winchester (Schuenemann et al., 2013; Taylor
99 et al., 2013; Mendum et al., 2014; Roffey et al., 2017) and one skeleton from a cemetery in Great
100 Chesterford, Essex (Schuenemann et al., 2018). Three of the Winchester skeletons yielded subtype
101 3I and the other three, as well as the Great Chesterford sample, were subtype 2F. To extend the
102 geographical range of our knowledge of ancient *M. leprae* subtypes in Britain, we carried out a
103 biomolecular examination of six skeletons from two sites from mediaeval England (Fig. 1), each
104 displaying pathological lesions indicative of leprosy though with varying degrees of ambiguity. We
105 report *M. leprae* genome sequences for three of these skeletons. Two of the genomes correspond to
106 subtype 3I, previously known in Britain, but the third is novel to Britain and highlights the role that
107 individual mobility might have played in adding complexity to the phylogeography of *M. leprae* in
108 mediaeval Europe.

109



110

111 **Fig. 1.** Locations of the sites from which skeletal samples were obtained.

112

113 **2. Material and methods**

114 *2.1 Skeletons*

115 Samples were selected, with permission, from the collection of the Biological Anthropological
116 Research Centre, University of Bradford, UK, based on various criteria. First, skeletons that clearly
117 show pathological rhinomaxillary changes indicative of leprosy were identified. Given that these
118 changes are pathognomonic for lepromatous leprosy, bilateral and symmetrical non-specific changes
119 in the lower limbs and feet of those skeletons are hypothesized to be associated with the disease as

120 well. Additionally, skeletons were sought that showed non-specific lesions in the lower limbs and feet
 121 as commonly seen in leprosy but where no rhinomaxillary alterations could be recorded, either
 122 because they were not present or because they could not be observed due to the state of
 123 preservation of the skeleton. The distribution of these lesions made the differential diagnosis of
 124 leprosy for these skeletons likely. The decision about which skeletal element and, in case of bilateral
 125 skeletal involvement, which side of the body would be sampled, was based on whether or not
 126 destruction was justifiable given the importance of the specimens for future studies.

127 Based on these criteria, samples were taken from six skeletons from two sites (Table 1,
 128 Supplementary Note). Skeletons C21, C35, C48 and C227 were excavated in 1989 from a cemetery
 129 that had belonged to the Hospital of St James and St Mary Magdalene, Chichester, UK. The original
 130 hospital was founded c.1118 AD and housed leprosy sufferers until being dissolved in 1442 AD and
 131 converted to an almshouse when the prevalence of leprosy declined in the UK (Magilton et al., 2008).
 132 Based on osteological data, C21 was a young adult male, C35 an adult of indeterminate sex, C48 a
 133 mature adult male, and C227 an adult, probable male. All four skeletons were dated to the 14th–17th
 134 century AD, based on historical documents and associated pottery (Magilton et al., 2008). Skeletons
 135 R5046 and R5256 were males of 17–25 and 25–35 years at age of death, respectively, from the late
 136 Anglo-Saxon churchyard cemetery at Raunds Furnells, Northamptonshire, UK, excavated during
 137 1977–1985. Stratigraphical analyses and radiocarbon dating suggested that the churchyard cemetery
 138 was in use from the mid-10th until mid-12th centuries (Boddington, 1996).

139

140 **Table 1**
 141 Details of skeletons and samples that were taken.
 142

Site	Skeleton	Sex, age at death	Leprosy indicators ^a			Elements sampled ^a
			Rhinomaxillary changes	Sub-periosteal new bone formation	Other changes	
Chichester	C21	Young adult male	Yes	Yes	Yes	Tibia, metatarsus
	C35	Adult, indeterminate sex	No	Yes	Yes	Tibia
	C48	Mature adult	Yes	Yes	Yes	Tibia, fibula
	C227	Male(?) adult	Yes	Yes	Yes	Calcaneus, phalanx
Raunds	R5046	Male, 17–25 years	Yes	Yes	Yes	Fibula
	R5256	Male 25–35 years	No	Yes	Yes	Tibia, fibula, new bone formation

143

144 ^a For details of lesions and elements sampled, see Supplementary Note (summary of archaeological
 145 sites, pathological lesions of skeletons, and elements that were sampled) and Supplementary Table 1
 146 (detailed osteological report).

147

148 Skeletons C21, C48 and C227 from Chichester and the Raunds skeleton R5046 displayed
 149 rhinomaxillary changes and other lesions indicative of leprosy (Table 1, Supplementary Note,
 150 Supplementary Table 1). The fourth Chichester skeleton, C35, did not show the typical rhinomaxillary

151 changes (the viscerocranium was absent) but had infective destruction of the talonavicular and
152 tibiotalar joints, an infection of the right calcaneus indicated by the presence of a draining sinus,
153 dorsal tarsal bars and sub-periosteal new bone formation on the tibiae, fibulae and feet. Individual
154 R5256 from Raunds also did not show the typical rhinomaxillary changes but had extensive sub-
155 periosteal new bone formation on other skeletal elements. Although initially reported as a case of
156 possible leprosy (Powell, 1996: 123), this pattern of bone formation is not specific to leprosy, and a
157 non-leprosy diagnosis has been suggested (Craig and Buckberry, 2010).

158

159 2.2 Ancient DNA regime

160 DNA extractions, PCRs and Illumina library preparations were performed in two physically
161 separated laboratories within the specialized ancient DNA research facility at the University of
162 Manchester. Each laboratory was supplied with ultra-filtered air under positive displacement. After
163 each use, benches and equipment were decontaminated by UV irradiation and by cleaning with 5%
164 hypochlorite acid, 70% ethanol and DNA Away (Molecular Bioproducts). Small equipment, plasticware
165 and UV-stable reagents were decontaminated by UV irradiation (254 nm, 120,000 mJ cm⁻² for 2 × 5
166 min, with 180° rotation between the two exposures) before use. Aqueous solutions were similarly
167 irradiated for 15 min. Personnel wore a disposable forensic suit, face mask, hair net, goggles, two
168 layers of gloves and disposable shoe covers at all times. DNA extractions were accompanied by two
169 blanks (normal extraction but without skeletal material) per five samples and every set of 5–7 PCRs
170 was accompanied by at least two blanks (set up with water rather than DNA extract).

171

172 2.3 DNA extraction, PCR and sequencing

173 Bone samples were taken using a hacksaw or electronic drill by personnel wearing protective
174 clothing, including forensic suits, hair nets, face masks and two pairs of sterile gloves. Samples were
175 placed in sterile plastic bags and stored under dry and cool conditions and transferred to the ancient
176 DNA facility. The bone surfaces were decontaminated by mechanical removal of the outer 1–2 mm of
177 each sample, followed by UV irradiation (254 nm, 120,000 mJ cm⁻²) for 2 × 5 min, with 180° rotation
178 between the two exposures (Bouwman et al., 2006). Bone samples were then placed in a DNA-free
179 plastic bag wrapped in a sterile piece of aluminium foil and crushed into fine powder. DNA was
180 extracted from 0.2 g of bone powder by standard methods (method D of Bouwman and Brown, 2002;
181 Dabney et al., 2013).

182 An initial screening for presence of *M. leprae* DNA was carried out by hemi-nested PCR directed
183 at the RLEP repetitive element, in 50 µl reactions comprising 2.5 µl of DNA extract or 1.0 µl of first
184 round PCR product, 1× AmpliTaq Gold PCR Master Mix (ThermoFisher Scientific), 2 mM MgCl₂, 200
185 µM dNTPs, 200 ng each primer, 1% bovine serum albumin and 1.25 units AmpliTaq Gold DNA
186 polymerase (ThermoFisher Scientific). The primers for the first PCR (forward: 5′–
187 CACCTGATGTTATCCCTTGC–3′; reverse: 5′–ATCATCGATGCACTGTTTAC–3) amplified a 133 bp
188 fragment, and the second PCR (forward: 5′–CATTTCTGCCGCTGGTATC–3′; reverse as for first
189 PCR) amplified a 111 bp fragment. Cycling conditions were 7 min at 95°C, followed by 35 cycles each
190 consisting of 1 min at 56°C, 1 min at 72°C, 1 min at 94°C, and a final cycle at 56°C for 1 min and

191 72°C for 10 min. PCR products were analysed by agarose gel electrophoresis and directly purified
192 using the QIAquick PCR product purification kit (Qiagen) prior to Sanger sequencing (GATC Biotech,
193 Cologne).

194 Dual-indexed libraries for Illumina sequencing were prepared from positive samples. No DNA
195 fragmentation step was performed as ancient DNA is already highly degraded. Library preparation
196 included a blunt-end repair step but no A-tailing, followed by purification using the MinElute PCR
197 purification kit (Qiagen), with elution in 20 µl. Subsequent adapter ligation was performed using p5
198 and p7 adapters at a concentration of 0.2 µM (Meyer and Kircher, 2010). Nicks from the previous step
199 were filled in with Bst polymerase before quantification by qPCR (Roche LightCycler 480) and
200 fluorimetry (Qubit 2.0) to determine the number of cycles required for the subsequent indexing PCR.
201 Sample-specific barcodes were added by double-indexing (Kircher et al., 2012), using KAPA HiFi
202 Uracil+ (Kapa Biosystems). Samples were then pooled in equimolar ratios and sequenced from both
203 ends in a single flow cell (Illumina HiSeq 4000). As well as shotgun sequencing, samples were also
204 sequenced after enrichment by in-solution hybridization capture (MYcroarray) according to the
205 manufacturer's instructions for degraded samples. RNA baits were transcribed from 80-mer
206 oligonucleotides complementary to the *M. leprae* TN genome to give an array with 2× tiling density.
207 Sequence data are curated at the European Nucleotide Archive under study accession number
208 PRJEB31393.

209

210 2.4 Data analysis

211 Raw sequencing data were pre-processed with AdapterRemoval 2.1 (Schubert et al., 2016) to
212 remove adapter sequence remnants, trim low quality bases and merge paired-end reads. Reads of at
213 least 25 bp which formed pairs with at least 11 bp overlap, and non-overlapping pair mates of >25 bp,
214 were retained in separate files. The paired-end reads were then mapped to the *M. leprae* TN genome
215 with BWA 0.7.12 (Li and Durbin, 2009). The alignments were cleaned by soft clipping, sorted based
216 on coordinate with Picard Tools (<http://broadinstitute.github.io/picard>), and mapped reads with a
217 quality score of at least 20 extracted using SAMtools 0.1.19 (Li et al., 2009). Read duplicates were
218 removed using the MarkDuplicates option in Picard Tools. The mapped reads with duplicates
219 removed were converted to Fasta files and tested by BLAST (Altschul et al., 1990) with the outputs
220 visualised using MEGAN 6 (Huson et al., 2016). Base quality score recalibration was performed with
221 GATK 3.6 (McKenna et al., 2010) using the non-human genome method. The recalibrated alignments
222 containing the reads that mapped to *M. leprae* and were verified by BLAST were visualized using
223 Geneious 8.1.9 (Kearse et al., 2012). Polymorphisms were considered genuine if supported by at
224 least 5× coverage and a variant frequency of at least 80%.

225

226 3. Results

227 Samples (Table 1) were screened for the presence of *M. leprae* DNA by hemi-nested polymerase
228 chain reactions (PCRs) directed at the multicopy RLEP element, which is believed to be specific to
229 this species (Braet et al., 2018) and has previously been used for detection of *M. leprae* ancient DNA
230 (Donoghue et al., 2017). The first-round PCRs provided products of the correct size, as judged by

231 agarose gel electrophoresis, for the two samples (tibia and metatarsus) taken from skeleton C21, the
 232 two samples (tibia and fibula) from C48, and the single sample (fibula) from R5046 (Table 2). The
 233 second-round PCRs provided bands of the expected sizes from the same samples, and no others.
 234 The results were replicated with a second set of PCRs on the same extracts. None of negative
 235 controls (extraction blanks and PCR blanks) revealed amplification products. Direct sequencing of the
 236 PCR products verified their identity as genuine RLEP amplicons.

237

238 **Table 2**

239 Results of RLEP PCRs.

240

Skeleton	Sampled element	PCR results ^a
C 21	Tibia	+,+
	Metatarsus	+,+
C 35	Tibia	-, -
C 48	Tibia	+,+
	Fibula	+,+
C227	Calcaneus	-, -
	Phalanx	-, -
R5046	Fibula	+,+
R5256	Tibia	-, -
	Fibula	-, -
	New bone formation	-, -

241

242 ^a Result of first hemi-nested PCR, result of second hemi-nested PCR.

243

244 Samples from the three positive skeletons – C21, C48 and R5046 – were further studied by
 245 Illumina sequencing. Shotgun sequencing was attempted for all three samples but less than 0.001%
 246 of the reads mapped to the *M. leprae* TN genome, which was insufficient for genome analysis. In-
 247 solution hybridization capture was therefore used to enrich the samples for *M. leprae* sequences.
 248 Enrichment dramatically increased the numbers of reads mapping to the reference genome
 249 (Supplementary Table 2), with >70% of the genome covered for each of the samples and a mean
 250 read depth of 4–10×. The data enabled the ancient strains to be assigned to *M. leprae* genotypes
 251 (Table 3) (Monot et al., 2009), revealing that C21 and C48 belong to subtype 3I and R5046 to subtype
 252 3K.

253

254 **Table 3**

255 Genotype assignments.

256

Skeleton	SNP position ^a	Type	SNP position ^a	Subtype
----------	---------------------------	------	---------------------------	---------

	14,676	1,642,875	2,935,685		413,902	1,133,492	2,312,059	3,267,975	
C21	C	T	C	3	G	T	C	G	I
C48	C	T	C	3	G	T	C	G	I
R5046	C	T	C	3	G	G	G	G	K

257

258 ^a SNP positions according to the *M. leprae* TN genome sequence.

259

260 Comparisons between different modern strains of *M. leprae* have revealed a total of 215
261 polymorphic sites (Monot et al., 2009). These sites were examined in the ancient *M. leprae* genomes
262 to determine whether the SNP version that was present was the same as in the *M. leprae* TN
263 reference sequence, or was the alternative SNP version present in some other modern genomes
264 (Supplementary Table 3). Of the three ancient genomes, R5046 was the most greatly diverged from
265 *M. leprae* TN, with 119 of the 183 SNPs (65.0%) that were covered by the ancient sequence
266 displaying the version not present in the reference genome. In comparison, 53.1% and 56.1% of the
267 SNPs covered in the C21 and C48 genomes, respectively, had the non-reference version. The
268 greater dissimilarity between R5046 and *M. leprae* TN reflects the greater phylogenetic distance
269 between subtype 3K and subtype 1A, to which TN belongs (Schuenemann et al., 2018). An additional
270 41 sites, comprising 30 SNPs and 11 indels, were specific to the three ancient genomes reported
271 here (Supplementary Table 4). Of the 30 SNPs, 18 were present only in the R5046 genome, and
272 seven and five were unique to C21 and C48, respectively. None of the 30 SNPs were present in all
273 three ancient genomes. Of the eleven indels, five were specific to R5046 and six were present in all
274 three samples, four of the latter in pseudogenes.

275

276 4. Discussion

277 We report the results of analyses of seven skeletons from two mediaeval sites in England, each
278 of the skeletons displaying osteological indicators of leprosy, though with different degrees of
279 ambiguity. We identified *M. leprae* DNA in three skeletons and following enrichment by in-solution
280 hybridization obtained sufficient sequence data to assign skeletons C21 and C48 to subtype 3I and
281 skeleton R5046 to subtype 3K. Although C21 and C48 came from the same cemetery, and were
282 curated together for 25 years prior to DNA analysis, we can be confident that both contain
283 endogenous *M. leprae* DNA (as opposed to cross-contamination between the skeletons or
284 contamination from a single external source) as their *M. leprae* genome sequences are non-identical.

285 Each of the three skeletons that produced positive results had extensive osteological indications
286 of leprosy, including rhinomaxillary changes, sub-periosteal new bone formation, and other
287 characteristic lesions on various skeletal elements. Of the samples that produced negative results,
288 C227 had a pathological condition most likely indicative of leprosy, in particular pencilling of the fifth
289 metatarsal with complete resorption of the head and distal part of the diaphysis in the right foot as well
290 as a slight pitting of the palate. However, this skeleton displayed relatively poor physical preservation,
291 indicating that the failure to detect *M. leprae* DNA was possibly due to biomolecular degradation
292 before the skeleton was excavated. Skeletons C35 and R5256 did not display rhinomaxillary changes,

293 weakening the diagnosis of leprosy in both cases. The pathology of the feet of skeleton C35 did
294 support a diagnosis of leprosy. R5256 had lesions characteristic of leprosy, but displayed new bone
295 formation on the *ossa coxae* and left scapula, skeletal elements that are not usually involved in
296 leprosy infection, possibly suggesting a systemic condition other than leprosy. Overall, the results
297 confirm those of other groups (Rafi et al., 1994; Taylor et al, 2000, 2006, 2013; Donoghue et al.,
298 2001, 2005, 2015; Inskip et al., 2015) by emphasising the value of ancient DNA analysis as a means
299 of providing independent support to palaeopathological identifications for leprosy.

300 *M. leprae* strains previously reported from mediaeval Britain and Ireland have been assigned to
301 subtypes 2F and 3I (Taylor et al., 2013, 2018; Schuenemann et al., 2013, 2018; Mendum et al.,
302 2014), the latter corresponding to branch 3 in the more recent phylogenetic classification
303 (Schuenemann et al., 2018). The discovery of subtype 3I in two skeletons from Chichester, dating to
304 the 14th–18th centuries AD, is therefore consistent with the results of these previous studies. Subtype
305 3K, however, has not previously been reported in Britain. In modern *M. leprae*, this subtype is
306 associated with East Asia, in particular Japan, China, the Philippines and New Caledonia
307 (Schuenemann et al., 2018). Among ancient specimens it has been detected in a Turkish skeleton
308 from the 8th–9th centuries AD (Erdal, 2004), three skeletons from Hungary, from the 7th–10th centuries
309 AD (Pálfi et al., 2002; Molnár et al., 2006; Schuenemann et al., 2018), and another from 11th–13th
310 century AD Denmark (Schuenemann et al., 2018). The R5046 skeleton is from a similar period (10th
311 to mid-12th centuries AD) as are these other European detections, but is the most westerly in location,
312 and hence the most distant from the modern distribution of the subtype. The distribution pattern raises
313 the intriguing possibility that the individual represented by skeleton R5046 did not contract leprosy in
314 Britain but instead had travelled to continental Europe and/or Asia and contracted the disease there. It
315 has previously been suggested that human mobility along the Silk Route was responsible for bringing
316 subtype 3K to Eastern Europe from its supposed centre of origin in East Asia (Monot et al., 2009).
317 During the Anglo-Saxon period, up until the 10th century AD, there was also extensive travel between
318 Britain and continental Europe, especially of educated clerics who taught and held religious positions
319 in various European countries (Palmer, 2009). One of the routes taken by travellers to reach the Holy
320 Land from West and Central Europe began in Vienna and passed along the Danube and the *Via*
321 *Diagonalis* to Constantinople, traversing Hungary, Serbia and Bulgaria (The Way to Jerusalem, 2018).
322 It is therefore possible that leprosy of subtype 3K was transmitted to Britain and other parts of
323 Western Europe by people who had travelled to the Holy Land and back via this route.

324

325 **Acknowledgements**

326 We thank Anthea Boylston (University of Bradford) for assistance with the osteological
327 examination, and Keri Brown (University of Manchester, UK) for assistance with sampling. This work
328 was funded by a studentship awarded by Majlis Amanah Rakyat (MARA) to A.K. and by the University
329 of Bradford and the University of Manchester.

330

331 **References**

332 Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J., 1990. Basic local alignment search

333 tool. *J. Mol. Biol.* 215, 403–410. [https://doi.org/10.1016/S0022-2836\(05\)80360-2](https://doi.org/10.1016/S0022-2836(05)80360-2).

334 Bennike, P., 2002. Vilhelm Moller-Christensen: his work and legacy, in: Roberts, C.A., Lewis, M.E.,
335 Manchester, K. (Eds.), *The Past and Present of Leprosy: Archaeological, Historical,*
336 *Palaeopathological and Clinical Approaches.* British Archaeological Reports International Series
337 1054, Archaeopress, Oxford, pp. 135–144.

338 Bhisagratna, K.K., 1996. *English Translation of Sushruta Samhita (ca 600 BC).* Bose, Calcutta.

339 Bloomfield, M., 2004. *Hymns of the Atharva Veda.* Kessinger Publishing, Whitefish.

340 Boddington, A., 1996. *Raunds Furnells: the Anglo-Saxon Church and Churchyard.* Archaeological
341 Report 7, English Heritage.

342 Boldsen, J.L., 2001. Epidemiological approach to the paleopathological diagnosis of leprosy. *Am. J.*
343 *Phys. Anthropol.* 115, 380–387. <https://doi.org/10.1002/ajpa.1094>.

344 Bouwman, A.S., Brown T.A., 2002. Comparison between silica-based methods for the extraction of
345 DNA from human bones from 18th–mid-19th century London. *Ancient Biomol.* 4, 173–178.
346 <https://doi.org/10.1080/1358612021000028470>.

347 Bouwman, A.S., Chilvers, E.R., Brown, K.A. & Brown T.A., 2006. Identification of the authentic
348 ancient DNA sequence in a human bone contaminated with modern DNA. *Am. J. Phys. Anthropol.*
349 131, 428–431. <https://doi.org/10.1002/ajpa.20411>.

350 Braet, S., Vandelannoote, K., Meehan, C.J., Brum Fontes, A.N., Hasker, E., Rosa, P.S., Lucena-
351 Silva, N., Rigouts, L., Suffys, P.N., De Jong, B.C., 2018. The repetitive element RLEP is a highly
352 specific target for detection of *Mycobacterium leprae*. *J. Clin. Microbiol.* 56, e01924-17.
353 <https://doi.org/10.1128/JCM.01924-17>.

354 Britton, W.J., Lockwood, D.N.J., 2004. Leprosy. *Lancet* 363, 1209–1219.
355 [https://doi.org/10.1016/S0140-6736\(04\)15952-7](https://doi.org/10.1016/S0140-6736(04)15952-7) (2004).

356 Craig, E.F., Buckberry, J.L., 2010. Investigating social status using evidence of biological status: a
357 case study from Raunds Furnells, in: Buckberry, J.L., Cherryson, A.K. (Eds.), *Burial in Later Anglo-*
358 *Saxon England, c. 650–1100.* Oxbow Books, Oxford, pp. 128–142.

359 Dabney, J., Knapp, M., Glocke, I., Gansauge, M.T., Weihmann, A., Nickel, B., Valdiosera, C., García,
360 N., Pääbo, S., Arsuaga, J.L., Meyer, M., 2013. Complete mitochondrial genome sequence of a
361 Middle Pleistocene cave bear reconstructed from ultrashort DNA fragments. *Proc. Natl. Acad. Sci*
362 *USA* 110, 15758–15763. <https://doi.org/10.1073/pnas.1314445110>.

363 Donoghue, H.D., Holton, J., Spigelman, M., 2001. PCR primers that can detect low levels of
364 *Mycobacterium leprae* DNA. *J. Med. Microbiol.* 50, 177–182. [https://doi.org/10.1099/0022-1317-50-](https://doi.org/10.1099/0022-1317-50-2-177)
365 [2-177](https://doi.org/10.1099/0022-1317-50-2-177).

366 Donoghue, H.D., Marcsik, A., Matheson, C., Vernon, K., Nuorala, E., Molto, J.E., Greenblatt, C.L.,
367 Spigelman, M., 2005. Co-infection of *Mycobacterium tuberculosis* and *Mycobacterium leprae* in
368 human archaeological samples: A possible explanation for the historical decline of leprosy. *Proc. R.*
369 *Soc. B* 272, 389–394. <https://doi.org/10.1098/rspb.2004.2966>.

370 Donoghue, H.D., Taylor, G.M., Marcsik, A., Molnar, A., Palfi, G., Pap, I., Teschler-Nicola, M., Pinhasi,
371 R., Erdal, Y.S., Velemínsky, P., Likovsky, J., Belcastro, M.G., Mariotti, V., Riga, A., Rubini, M., Zaiio,
372 P., Besra, G.S., Lee, O.Y., Wu, H.H., Minnikin, D.E., Bull, I.D., O'Grady, J., Spigelman, M., 2015. A

373 migration-driven model for the historical spread of leprosy in mediaeval Eastern and Central
374 Europe. *Infect. Genet. Evol.* 31, 250–256. <https://doi.org/10.1016/j.meegid.2015.02.001>.

375 Donoghue, H.D., Taylor, G.M., Stewart, G.R., Lee, O.Y.-C., Wu, H.H.T., Besra, G.S., Minnikin, D.E.,
376 2017. Positive diagnosis of ancient leprosy and tuberculosis using ancient DNA and lipid
377 biomarkers. *Diversity* 9(4), 46. <https://doi.org/10.3390/d9040046>.

378 Dzierzykray-Rogalski, T., 1980. Paleopathology of the Ptolemaic inhabitants of Dakhleh Oasis
379 (Egypt). *J. Hum. Evol.* 9, 71–72. [https://doi.org/10.1016/0047-2484\(80\)90044-5](https://doi.org/10.1016/0047-2484(80)90044-5).

380 Erdal, Y.S., 2004. Health status of the Kovuklukaya (Boyabat/Sinop) people and its relations with their
381 lifestyle. *Anadolu Arařtırmaları* 22, 169–196.

382 Grzybowski, A., Sak, J., Pawlikowski, J., Nita, M., 2016. Leprosy: social implications from antiquity to
383 the present. *Clin. Dermatol.* 34, 8–10, <https://doi.org/10.1016/j.clindermatol.2015.10.009>.

384 Han, X.Y., Seo, Y.H., Sizer, K.C., Schoberle, T., May, G.S., Spencer, J.S., Li, W., Nair, R.G., 2008. A
385 new mycobacterium species causing diffuse lepromatous leprosy. *Am. J. Clin. Pathol.* 130, 856–
386 864. <https://doi.org/10.1309/AJCPP72FJZZRRVMM>.

387 Hansen, G.H.A., 1874. Undersøgelser Angående Spedalskhedens Årsager. *Norsk Mag.*
388 *Laegervidenskaben.* 4, 1–88.

389 Hulse, E.V., 1972. Leprosy and Ancient Egypt. *Lancet* 2, 1024. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(72)92636-0)
390 [6736\(72\)92636-0](https://doi.org/10.1016/S0140-6736(72)92636-0).

391 Huson, D.H., Beier, S., Flade, I., Górska, A., El-Hadidi, M., Mitra, S., Ruscheweyhm H.J., Tappu, R.,
392 2016. MEGAN community edition – interactive exploration and analysis of large-scale microbiome
393 sequencing data. *PLoS Comput. Biol.* 12(6), e1004957.
394 <https://doi.org/10.1371/journal.pcbi.1004957>.

395 Inskip, S.A., Taylor, G.M., Zakrzewski, S.R., Mays, S.A., Pike, A.W.G., Llewellyn, G., Williams, C.M.,
396 Lee, O.Y., Wu, H.H., Minnikin, D.E., Besra, G.S., Stewart, G.R., 2015. Osteological, biomolecular
397 and geochemical examination of an early Anglo-Saxon case of lepromatous leprosy. *PLoS ONE* 10,
398 e0124282. <https://doi.org/10.1371/journal.pone.0124282>.

399 Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A.,
400 Markowitz, S., Duran, C., Thierer, T., Ashton, B., Meintjes, P., Drummond, A., 2012. Geneious
401 basic: an integrated and extendable desktop software platform for the organization and analysis of
402 sequence data. *Bioinformatics* 28, 1647–1649. <https://doi.org/10.1093/bioinformatics/bts199>.

403 Kircher, M., Sawyer, S., Meyer, M., 2012. Double indexing overcomes inaccuracies in multiplex
404 sequencing on the Illumina platform. *Nucl. Acids Res.* 40(1), e3. <https://doi.org/10.1093/nar/gkr771>.

405 Lenk, E.J., Redekop, W.K., Luyendijk, M., Fitzpatrick, C., Niessen, L., Stolk, W.A., Tediosi, F.,
406 Rijnsburger, A.J., Bakker, R., Hontelez, J.A.C., Richardus, J.H., Jacobson, J., Le Rutte, E.A., de
407 Vlas, S.J., Severeens, J.L., 2018. Socioeconomic benefit to individuals of achieving 2020 targets for
408 four neglected tropical diseases controlled/eliminated by innovative and intensified disease
409 management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease.
410 *PLoS Negl. Trop. Dis.* 12(3), e0006250. <https://doi.org/10.1371/journal.pntd.0006250>.

411 Leung, A.K.C., 2008. *Leprosy in China: a history*. Columbia University Press, New York.

412 Li, H., Durbin, R., 2009. Fast and accurate short read alignment with Burrows-Wheeler transform.
413 Bioinformatics 15, 1754–1760. <https://doi.org/10.1093/bioinformatics/btp698>.

414 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin,
415 R., 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079.
416 <https://doi.org/10.1093/bioinformatics/btp352>.

417 Magilton, J., Lee, F., Boylston, A., 2008. ‘Lepers Outside the Gate’: Excavation at the Cemetery of the
418 Hospital of St James and St Mary Magdelene, Chichester, 1986-87 and 1993. CBA Research report
419 158, Council for British Archaeology, York.

420 Masaki, T., Qu, J., Cholewa-Waclaw, J., Burr, K., Raaum, R., Rambukkana, A., 2013.
421 Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination
422 of infection. Cell 152, 51–67. <https://doi.org/10.1016/j.cell.2012.12.014>.

423 McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K.,
424 Altshuler, D., Gabriel, S., Daly, M., DePristo, M.A., 2010. The Genome Analysis Toolkit: a
425 MapReduce framework for analysing next-generation DNA sequencing data. Genome Res. 20,
426 1297–1303. <https://doi.org/10.1101/gr.107524.110>.

427 McLeod, K., Yates, R., 1981. Forms of Ch'in law: an annotated translation of the Feng-chen shih.
428 Harv. J. Asiat. Stud. 41, 111–163. <https://doi.org/10.2307/2719003>.

429 Mendum, T.A., Schuenemann, V.J., Roffey, S., Taylor, G.M., Wu, H., Singh, P., Tucker, K., Hinds, J.,
430 Cole, S.T., Kierzek, A.M., Nieselt, K., Krause, J., Stewart, G.R., 2014. *Mycobacterium leprae*
431 genomes from a British mediaeval leprosy hospital: towards understanding an ancient epidemic.
432 BMC Genomics 15, 270. <https://doi.org/10.1186/1471-2164-15-270>.

433 Meyer, M., Kircher, M., 2010. Illumina sequencing library preparation for highly multiplexed target
434 capture and sequencing. Cold Spring Harb. Protoc. 2010(6), pdb.prot5448.
435 <https://doi.org/10.1101/pdb.prot5448>.

436 Molnár, E., Marcsik, A., Bereczki, Z., Donoghue, H.D., 2006. Pathological cases from the 7th century
437 in Hungary, in Paleopathology Association, 16th European Meeting, Scientific Program and
438 Abstracts. Supplement to Paleopathology Newsletter, pp. 36–37.

439 Monot, M., Honoré, N., Garnier, T., Zidane, N., Sherafi, D., Paniz-Mondolfi, A., Matsuoka, M., Taylor,
440 G.M., Donoghue, H.D., Bouwman, A., Mays, S., Watson, C., Lockwood, D., Khamesipour, A.,
441 Dowlati, Y., Jianping, S., Rea, T.H., Vera-Cabrera, L., Stefani, M.M., Banu, S., Macdonald, M.,
442 Sapkota, B.R., Spencer, J.S., Thomas, J., Harshman, K., Singh, P., Busso, P., Gattiker, A.,
443 Rougemont, J., Brennan, P.J., Cole, S.T., 2009. Comparative genomic and phylogeographic
444 analysis of *Mycobacterium leprae*. Nat. Gen. 42, 1282–1289. <https://doi.org/10.1038/ng.477>.

445 Ortner, D.J., 2003. Identification of Pathological Conditions in Human Skeletal Remains, second ed.
446 Academic Press, London.

447 Pálfi, G., Zink, A., Haas, C.J., Marcsik, A., Dutour, O., Nerlich, A.G., 2002. Historical and
448 palaeopathological evidence of leprosy in Hungary, in: Roberts, C.A., Lewis, M.E., Manchester, K.
449 (Eds.), The Past and Present of Leprosy: Archaeological, Historical, Palaeopathological and Clinical
450 Approaches. British Archaeological Reports International Series 1054, Archaeopress, Oxford, pp.
451 205–209.

452 Palmer, J.T., 2009. Anglo-Saxons in a Frankish World, 690–900. Brepols, Turnhout.

453 Pinhasi, R., Foley, R., Donoghue, H.D., 2005. Reconsidering the antiquity of leprosy. *Science* 312,
454 846. <https://doi.org/10.1126/science.312.5775.846a>.

455 Powell, F. 1996. The human remains, in Boddington, A. (Ed.), *Raunds Furnells: The Anglo-Saxon*
456 *Church and Churchyard*. English Heritage Archaeological Report 7, London, pp. 113–124.

457 Rafi, A., Spigelman, A., Stanford, J., Lemma, E., Donoghue, H., Zias, J., 1994. DNA of
458 *Mycobacterium leprae* detected by PCR in ancient bone. *Int. J. Osteoarchaeol.* 4, 287–290.
459 [https://doi.org/10.1016/S0140-6736\(94\)92494-5](https://doi.org/10.1016/S0140-6736(94)92494-5).

460 Reader, R., 1974. New evidence for the antiquity of leprosy in early Britain. *J. Archaeol. Sci.* 1, 205–
461 207. [https://doi.org/10.1016/0305-4403\(74\)90043-0](https://doi.org/10.1016/0305-4403(74)90043-0).

462 Robbins, G., Tripathy, M., Misra, V.N., Mohanty, R.K., Shinde, V.S., Gray, K.M., Schug, M.D., 2009.
463 Ancient skeletal evidence for leprosy in India (2000 B.C.). *PLoS ONE* 4(5), 1-
464 8. <https://doi.org/10.1371/journal.pone.0005669>.

465 Roberts, C., Manchester, K., 2010. *The Archaeology of Disease*, third ed. The History Press, Stroud.

466 Roberts, C.A., 2002. The antiquity of leprosy in Britain: the skeletal evidence, in: Roberts, C.A., Lewis,
467 M.E., Manchester, K. (Eds.), *The Past and Present of Leprosy: Archaeological, Historical,*
468 *Palaeopathological and Clinical Approaches*. British Archaeological Reports International Series
469 1054, Archaeopress, Oxford, pp. 213–222.

470 Roffey, S., Tucker, K., Filipek-Ogden, K., Montgomery, J., Cameron, J., O’Connell, T., Evans, J.,
471 Marter, P., Taylor, G.M., 2017. Investigation of a medieval pilgrim burial excavated from the
472 *leprosarium* of St Mary Magdalen Winchester, UK. *PLoS Negl. Trop. Dis.* 11(1), e0005186.
473 <https://doi.org/10.1371/journal.pntd.0005186>.

474 Schubert, M., Lindgreen, S., Orlando, L., 2016. AdapterRemoval v2: rapid adapter trimming,
475 identification, and read merging. *BMC Res. Notes* 9, 88. [https://doi.org/10.1186/s13104-016-1900-](https://doi.org/10.1186/s13104-016-1900-2)
476 [2](https://doi.org/10.1186/s13104-016-1900-2).

477 Schuenemann, V.J., Singh, P., Mendum, T.A., Krause-Kyora, B., Jager, G., Bos, K.I., Herbig, A.,
478 Economou, C., Benjak, A., Busso, P., Nebel, A., Boldsen, J.L., Kjellström, A., Wu, H., Stewart, G.R.,
479 Taylor, G.M., Bauer, P., Lee, O.Y.-C., Wu, H.H.T., Minnikin, D.E., Besra, G.S., Tucker, K., Roffey,
480 S., Sow, S.O., Cole, S.T., Nieselt, K., Krause, J., 2013. Genome-wide comparison of mediaeval and
481 modern *Mycobacterium leprae*. *Science* 341, 179–183. <https://doi.org/10.1126/science.1238286>.

482 Schuenemann, V.J., Avanzi, C., Krause-Kyora, B., Seitz, A., Herbig, A., Inskip, S., Bonazzi, M.,
483 Reiter, E., Urban, C., Dangvard Pedersen, D., Taylor, G.M., Singh, P., Stewart, G.R., Velemínský,
484 P., Likovsky, J., Marcsik, A., Molnár, E., Pálfi, G., Mariotti, V., Riga, A., Belcastro, M.G., Boldsen,
485 J.L., Nebel, A., Mays, S., Donoghue, H.D., Zakrzewski, S., Benjak, A., Nieselt, K., Cole, S.T.,
486 Krause, J., 2018. Ancient genomes reveal a high diversity of *Mycobacterium leprae* in mediaeval
487 Europe. *PLoS Pathog.* 14(5), e1006997. <https://doi.org/10.1371/journal.ppat.1006997>.

488 Singh, P., Cole, S.T., 2011. *Mycobacterium leprae*: genes, pseudogenes and genetic diversity. *Future*
489 *Microbiol.* 6, 57–71, <https://doi.org/10.2217/fmb.10.153>.

490 Taylor, G.M., Widdison, S., Brown, I.N., Young, D., 2000. A mediaeval case of lepromatous leprosy
491 from 13th–14th century Orkney, Scotland. *J. Archaeol. Sci.* 27, 1133–1138.

492 <https://doi.org/10.1006/jasc.1999.0532>.

493 Taylor, G.M., Watson, C.L., Bouwman, A.S., Lockwood, D.N.J., Mays, S.A., 2006. Variable number
494 tandem repeat (VNTR) typing of two palaeopathological cases of lepromatous leprosy from
495 mediaeval England. *J. Archaeol. Sci.* 33, 1569–1579. <https://doi.org/10.1016/j.jas.2006.02.008>.

496 Taylor, G.M., Tucker, K., Butler, R., Pike, A.W.G., Lewis, J., Roffey, S., Marter, P., Lee, O.Y., Wu,
497 H.H., Minnikin, D.E., Besra, G.S., Singh, P., Cole, S.T., Stewart, G.R., 2013. Detection and strain
498 typing of ancient *Mycobacterium leprae* from a mediaeval leprosy hospital. *PLoS ONE* 8, e62406.
499 <https://doi.org/10.1371/journal.pone.0062406>.

500 Taylor, G.M., Murphy, E.M., Mendum, T.A., Pike, A.W.G., Linscott, B., Wu, H., O'Grady, J.,
501 Richardson, H., O'Donovan, E., Troy, C., Stewart, G.R., 2018. Leprosy at the edge of Europe –
502 biomolecular, isotopic and osteoarchaeological findings from medieval Ireland. *PLoS ONE* 13,
503 e0209495. <https://doi.org/10.1371/journal.pone.0209495>.

504 *The Way to Jerusalem*, 2018. Historical routes: routes to the Holy Land.
505 <http://www.waytojerusalem.com/en/historical-routes/routes-to-the-holy-land>.

506 World Health Organization, 2018. Global leprosy update, 2017: reducing the disease burden due to
507 leprosy. *Wkly Epidemiol. Rec.* 93, 445–456. <https://apps.who.int/iris/handle/10665/274290>.